Advancements in clinical trials and therapeutic development offer new hope for patients with spinal cord injuries (SCI) and ankylosing spondylitis (AS). Several companies are diligently working to develop novel treatments, with promising therapies emerging in various phases of clinical trials.
Spinal Cord Injury: Emerging Therapies and Clinical Trials
DelveInsight's assessment indicates a robust pipeline of over 35 key companies developing more than 35 treatment therapies for SCI. These therapies encompass a range of mechanisms of action, including stem cell therapy, neuroprotection, and regenerative medicine.
Key companies in the SCI therapeutics market include Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, NervGen Pharma, and StemCyte, Inc. Emerging therapies in clinical trials include allogeneic stem cell therapy (Athersys), OLT1177 (Olatec Therapeutics), ALMB0166 (AlaMab therapeutics), AXER-204 (ReNetX Bio), FAB117-HC (Histocell), AST-OPC1 (Lineage Cell Therapeutics), Elezanumab (AbbVie), MT 3921 (Mitsubishi Tanabe Pharma), PMZ-1620 (Pharmazz), ES 135 (Eusol Biotech), KP-100IT (Kringle Pharma), NVG-291 (NervGen Pharma), Romosozumab, and Umbilical Cord Blood Mononuclear Cell (StemCyte, Inc).
Neuroplast, a Dutch biotech company, has completed patient enrollment for its Phase II clinical trial assessing Neuro-Cells® in treating traumatic SCI (TSCI). Initial findings indicate a promising safety profile with no reported adverse events related to the product. In July 2023, NeuroSolv Therapeutics sought investment for clinical trials of Perineline™, a therapy with the potential to benefit approximately two million individuals worldwide grappling with SCI.
Ankylosing Spondylitis: Novel Treatments and Clinical Advancements
The ankylosing spondylitis pipeline consists of over 20 key companies continuously working towards developing more than 20 treatment therapies. These therapies aim to address the chronic inflammatory condition primarily affecting the spine and sacroiliac joints.
Companies such as Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, and Amgen are actively involved in developing treatments for AS. Emerging therapies in different phases of clinical trials include KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, and Apremilast.
UCB Biopharma presented new two-year data for bimekizumab (bimekizumab-bkzx) at the American College of Rheumatology (ACR) Convergence 2024, demonstrating sustained improvements in clinical and patient-reported outcomes for AS. MoonLake Immunotherapeutics is actively working on Phase 3 clinical trials for sonelokimab. In October 2023, AbbVie's RINVOQ was prescribed for adults with active AS who have not responded satisfactorily to conventional therapy. Also in October 2023, bimekizumab received approval in the European Union for addressing moderate to severe plaque psoriasis and active psoriatic arthritis and active axSpA in adults.
